MacroGenics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving MacroGenics, Inc. now
Current reporting with the operating signal separated from the noise.
B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity
The story matters when it changes MacroGenics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript
Investors are testing whether MacroGenics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MacroGenics, Inc. to Announce 2024 Financial Results on March 20, 2025
The story matters when it changes MacroGenics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2022 Results
The story matters when it changes MacroGenics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest MGNX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
MacroGenics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →